Combining cell-based therapies and neural prostheses to promote neural survival

Simple item page
dc.contributor.authorWise, Andrew
dc.contributor.authorFallon, James
dc.contributor.authorNeil, Alison
dc.contributor.authorPettingill, Lisa
dc.contributor.authorGeaney, Marilyn
dc.contributor.authorSkinner, Stephen
dc.contributor.authorShepherd, Robert
dc.date.accessioned2013-08-01T06:54:50Z
dc.date.available2013-08-01T06:54:50Z
dc.date.issued2011-10
dc.description.abstractCochlear implants provide partial restoration of hearing for profoundly deaf patients by electrically stimulating spiral ganglion neurons (SGNs); however, these neurons gradually degenerate following the onset of deafness. Although the exogenous application of neurotrophins (NTs) can prevent SGN loss, current techniques to administer NTs for long periods of time have limited clinical applicability. We have used encapsulated choroid plexus cells (NTCells; Living Cell Technologies, Auckland, New Zealand) to provide NTs in a clinically viable manner that can be combined with a cochlear implant. Neonatal catswere deafened and unilaterally implanted with NTCells and a cochlear implant. Animals received chronic electrical stimulation (ES) alone, NTs alone, or combined NTs and ES (ES + NT) for a period of as much as 8 months. The opposite ear served as a deafened unimplanted control. Chronic ES alone did not result in increased survival of SGNs or their peripheral processes. NT treatment alone resulted in greater SGN survival restricted to the upper basal cochlear region and an increased density of SGN peripheral processes. Importantly, chronic ES in combination with NTs provided significant SGN survival throughout a wider extent of the cochlea, in addition to an increased peripheral process density. Re-sprouting peripheral processes were observed in the scala media and scala tympani, raising the possibility of direct contact between peripheral processes and a cochlear implant electrode array. We conclude that cell-based therapy is clinically viable and effective in promoting SGN survival for extended durations of cochlear implant use. These findings have important implications for the safe delivery of therapeutic drugs to the cochlea.en_US
dc.description.sponsorshipFunding was provided by the National Institutes of Health (HHS-N-263-2007-00053-C), The Garnett Passe and Rodney Williams Memorial Foundation, and the NH&MRC. The authors would like to acknowledge the support from the State Government of Victoria’s Operational Infrastructure Program.en_US
dc.identifier.citationWise, A. K., Fallon, J. B., Neil, A. J., Pettingill, L. N., Geaney, M. S., Skinner, S. J., & Shepherd, R. K. (2011). Combining cell-based therapies and neural prostheses to promote neural survival. Neurotherapeutics, 8(4), 774-787.en_US
dc.identifier.issn1878-7479
dc.identifier.urihttp://repository.bionicsinstitute.org:8080/handle/123456789/39
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectCell Survival - Drug effectsen_US
dc.subjectCochlear Implantation - Methodsen_US
dc.subjectDeafness - Drug therapyen_US
dc.subjectDeafness - Surgeryen_US
dc.subjectElectric Stimulation - Methodsen_US
dc.subjectEvoked Potentials, Auditory, Brain Stemen_US
dc.subjectNerve Growth Factors - Therapeutic useen_US
dc.subjectNeural Prosthesesen_US
dc.subjectNeurofilament Proteinsen_US
dc.subjectTissue Therapy - Methodsen_US
dc.titleCombining cell-based therapies and neural prostheses to promote neural survivalen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2011_Wise-Cellbased.pdf
Size:
247.46 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
BI publications